Author: Ribero, S; Giura, M T; Viola, R; Ramondetta, A; Siliquini, N; Cardone, P; Tonella, L; Quaglino, P; Dapavo, P; Panzone, M; Ortoncelli, M; Fierro, M T
Title: Effectiveness and Safety of Dupilumab for the Treatment of Atopic Dermatitis in Adult Cohort: a Real-Life Italian Tertiary Centre Experience. Cord-id: yoq2rsna Document date: 2020_1_20
ID: yoq2rsna
Snippet: Atopic dermatitis (AD) is a chronic inflammatory skin disease affecting 7-10% of adults1 . The systemic treatment for moderate-to-severe AD was limited, but a new biologic drug (Dupilumab) was recently approved. It is a fully human monoclonal antibody directed against the alpha-subunit of the interleukin-4-receptor, blocking signalling of both Th2-cytokines IL-4 and IL-13. The effectiveness and safety was demonstrated in clinical trials2-4 , but these studies do not reflect conditions in daily p
Document: Atopic dermatitis (AD) is a chronic inflammatory skin disease affecting 7-10% of adults1 . The systemic treatment for moderate-to-severe AD was limited, but a new biologic drug (Dupilumab) was recently approved. It is a fully human monoclonal antibody directed against the alpha-subunit of the interleukin-4-receptor, blocking signalling of both Th2-cytokines IL-4 and IL-13. The effectiveness and safety was demonstrated in clinical trials2-4 , but these studies do not reflect conditions in daily practice.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date